Neoleukin Therapeutics (NASDAQ:NLTX – Get Rating) had its price objective decreased by HC Wainwright from $22.00 to $6.00 in a report issued on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other analysts also recently weighed in on the stock. Piper Sandler decreased their price target on shares of Neoleukin Therapeutics from $25.00 to $6.00 in a research report on Friday, May 27th. Canaccord Genuity Group reissued a buy rating and set a $10.00 price target on shares of Neoleukin Therapeutics in a research report on Wednesday, July 6th.
Neoleukin Therapeutics Trading Down 1.8 %
NLTX stock opened at $1.07 on Monday. Neoleukin Therapeutics has a twelve month low of $0.80 and a twelve month high of $8.48. The company has a market capitalization of $45.56 million, a P/E ratio of -0.95 and a beta of 1.08. The firm has a 50 day simple moving average of $1.08 and a 200-day simple moving average of $1.33.
Hedge Funds Weigh In On Neoleukin Therapeutics
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
- Get a free copy of the StockNews.com research report on Neoleukin Therapeutics (NLTX)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn’t Differentiate, But it’s Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.